PSMA-Targeted Cancer Immunotherapy Patent Granted to Methodist Hospital

Tue, 21 Apr 2026 10:47:50 +0000
Intellectual Property

The USPTO granted patent US12605446B2 to The Methodist Hospital covering engineered cells with chimeric antigen receptors (CARs) targeting PSMA for prostate cancer treatment. The patent, filed August 20, 2021, contains 15 claims and names Bin He as inventor. This grant confers exclusive IP rights for PSMA-targeted CAR-T immunotherapies in the United States.